Primary Analysis of a Phase II Study of Atezolizumab plus Bevacizumab for TACE-Unsuitable Patients with Tumor Burden beyond Up-To-Seven Criteria in Intermediate-Stage Hepatocellular Carcinoma: REPLACEMENT Study
Atezolizumab plus bevacizumab appears beneficial as first-line treatment for TACE-unsuitable patients with unresectable intermediate-stage unresectable HCC beyond up-to-seven criteria. Future strategies utilizing multimodal approaches may further improve outcomes.
Authors
- Michihisa Moriguchi (ORCID: https://orcid.org/0000-0001-9779-4369)
- Yasuhito Tanaka (ORCID: https://orcid.org/0000-0002-2473-6966)
- Ryosuke Tateishi (ORCID: https://orcid.org/0000-0003-3021-2517)
- Kaoru Tsuchiya (ORCID: https://orcid.org/0000-0003-0436-5915)
- Masafumi Ikeda (ORCID: https://orcid.org/0000-0002-4050-2086)
- Kazushi Numata (ORCID: https://orcid.org/0000-0003-4671-4431)
- Masatoshi Kudo (ORCID: https://orcid.org/0000-0002-4102-3474)
- Shigeo Shimose (ORCID: https://orcid.org/0000-0003-2068-8386)
- Hiroshi Aikata (ORCID: https://orcid.org/0000-0002-3409-2156)
- Atsushi Hiraoka (ORCID: https://orcid.org/0000-0003-1989-0480)
- Shinji Itoh (ORCID: https://orcid.org/0000-0003-0382-2520)
- Yuzo Kodama (ORCID: https://orcid.org/0000-0003-1223-7147)
- Hidekatsu Kuroda (ORCID: https://orcid.org/0000-0002-1471-1087)
- Kazuomi Ueshima (ORCID: https://orcid.org/0000-0002-7577-5789)
- Tatsuya Yamashita (ORCID: https://orcid.org/0000-0002-3602-8086)
- Kouji Yamamoto (ORCID: https://orcid.org/0000-0003-0696-9659)
- Sadahisa Ogasawara (ORCID: https://orcid.org/0000-0002-6540-9064)
Institutions
- Kurume University (JP)
- Kyushu University (JP)
- Chiba University (JP)
- Iwate Medical University (JP)
- Yokohama City University Medical Center (JP)
- Kyoto Prefectural University of Medicine (JP)
- Kanazawa University Hospital (JP)
- Hiroshima Prefectural Hospital (JP)
- National Cancer Center Hospital East (JP)
- Ehime Prefectural Central Hospital (JP)
- Musashino Red Cross Hospital (JP)
- Kobe University (JP)
- The University of Tokyo (JP)
- Yokohama City University (JP)
- Kindai University (JP)
- Kumamoto University (JP)
Publication Details
- Journal
- Liver Cancer
- Published
- 2025-06-19
- DOI
- https://doi.org/10.1159/000546899
- Citations
- 4
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 5.29
Funders
- Chugai Pharmaceutical